solid tumours

Oncology

In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.

Oncology

Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.

News

Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.

News

Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.

Oncology

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.